MOR News and Press, MorphoSys AG From 08/10/23

2023-08-10 11:40:10 ET MorphoSys AG (MOR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and...

2023-08-09 16:52:31 ET MorphoSys press release ( NASDAQ: MOR ): Q2 GAAP EPS of -€$2.16. Revenue of €53.2M (-10.4% Y/Y). For further details see: MorphoSys GAAP EPS of -€$2.16, revenue of €$53.2M

– Monjuvi ® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 ȁ...

2023-06-16 19:30:59 ET JP Morgan has upgraded MorphoSys ( NASDAQ: MOR ) to overweight, citing upcoming data from a Phase 3 clinical study for its drug pelabresib in the treatment of myelofibrosis, a type of bone marrow cancer. The investment bank said that positive results would...

2023-06-16 08:33:21 ET Virgin Galactic  ( SPCE ) +42% stock movers today: Virgin Galactic, Coherent and more. VCI Global ( VCIG ) +35% Marks Debut into Artificial Intelligence (“AI”) and Big Data Industries Through Partnership with Fusionex. ...

2023-06-14 08:32:02 ET Advanced Health Intelligence ( AHI ) -25% . Eastside Distilling ( EAST ) -24% on plans for exchanging debt for equity with lenders . Coeptis Therapeutics Holdings ( COEP ) -21% . IperionX Limited ( IPX ) -16% . IO ...

2023-05-22 11:17:03 ET Summary Sales beat: Despite Monjuvi's setbacks, MorphoSys exceeds Q1 2023 sales expectations with €62.3m and robust 11% YoY US growth. Pelabresib Potential: Accelerated MANIFEST-2 Pelabresib data readout could be a key catalyst, promising MF candidate...

2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...

2023-05-06 03:08:07 ET MorphoSys AG (MOR) Q1 2023 Earnings Conference Call May 04, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Develo...

2023-05-03 17:37:36 ET MorphoSys press release ( NASDAQ: MOR ): Q1 GAAP EPS of -€1.30. Revenue of €62.3M (+50.1% Y/Y). Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023. €79...